iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Mankind Pharma Ltd Option Chain

2,570.2
(0.02%)
Sep 17, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ol (lots)Call PriceStrike PricePut PriceOl (lots)
--2,000₹1.1 0%1,8000%
--2,100₹3.5 0%00%
--2,200₹0.8 0%6,0750%
--2,250₹1.7 0%10,8000%
2250%₹279.2 0%2,300₹2.45 0%20,0250%
9000%₹252.85 0%2,350₹3.6 -12.19%6,525-6.45%
4500%₹183.45 0%2,400₹7.1 3.64%19,3504.87%
4,7250%₹150.25 0%2,450₹11.65 -14.33%22,72548.52%
21,6005.49%₹102 -2.62%2,500₹22.05 -6.76%34,6502.66%
19,125-5.55%₹70.7 -3.74%2,550₹40.3 0.24%20,70058.62%
1,41,30018.49%₹47 -4.17%2,600₹63.35 -5.51%48,825-1.36%
44,5503.12%₹28.95 -7.5%2,650₹91 0%3,1500%
97,2004.34%₹17 -10.76%2,700₹139.25 3.14%5,17576.92%
31,27518.80%₹9.5 -15.55%2,750₹187.65 0%2250%
57,1504.52%₹6.25 -7.4%2,800₹232.25 0%4500%
7,2000%₹3.5 0%2,850₹276.55 9.65%2,250150%
17,3250%₹2.8 3.7%2,900₹295.5 0%9000%
5,4000%₹1.1 0%3,000--

Mankind Pharma: Related NEWS

Mankind Pharma Q1 Updates: Net profit down ~18%

The company also informed that its diluted earnings per share (EPS) slipped by 20.10% on a yearly basis to ₹10.60.

1 Aug 2025|01:41 PM
Read More
Top Stocks for Today - 01st August 2025

Here are some of the stocks that may see significant price movement today: Coal India, Mankind Pharma, Swiggy, etc.

1 Aug 2025|08:58 AM
Read More
Mankind Pharma posts mixed performance in Q4; stock slips ~4%

The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25.

22 May 2025|12:15 PM
Read More
Top Stocks for Today - 22nd May 2025

Here are some of the stocks that may see significant price movement today: NBCC, IndusInd Bank, Hindustan Zinc, etc.

22 May 2025|06:38 AM
Read More
Mankind Pharma Faces ₹183.11 Crore Tax Demand

The cumulative demand, including interest charges, is ₹183.11 crore.

30 Mar 2025|04:34 PM
Read More
Mankind Pharma Merges Three Subsidiaries

The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.

30 Mar 2025|01:33 PM
Read More
Mankind Pharma Faces ₹111.68 Crore Tax Demand, Plans to Appeal

The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.

28 Feb 2025|11:13 PM
Read More
Top Stocks for Today - 24th January 2025

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

24 Jan 2025|07:50 AM
Read More
Mankind Pharma Q3 Profit Falls 16%, Revenue Jumps 24%

The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.

23 Jan 2025|11:57 PM
Read More
Mankind Pharma Secures ₹5,000 Crore NCDs by Pledging 56.31% Stake in BSV

The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.

8 Jan 2025|04:01 PM
Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.